FierceBiotech Radio on Gilead's maxed-out revenue and BioMarin's FDA struggles

In an episode free of Valeant Pharmaceuticals ($VRX) and Martin Shkreli, FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a Senate investigation into Gilead Sciences' ($GILD) pricing of the hepatitis C drug Sovaldi, BioMarin's ($BMRN) efforts to win approval for a rare disease treatment and GlaxoSmithKline's latest woes in China.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.